Samsung Biologics Q2 2026: Revenue KRW 1,321B, Up 30%; Cumulative Contract Value Reaches USD 21.6B

Plants 1–4 ran at full utilization with operating profit of KRW 586.4B and an operating margin of 44.4%; Plant 5 PPQ batches are ramping, and the company expects to hit the upper end of its 15–20% full-year revenue growth guidance.

On July 23, Samsung Biologics (207940.KS) reported Q2 2026 results: revenue of KRW 1,321B (+30.2% YoY), operating profit of KRW 586.4B, and EBITDA of KRW 698.5B. First-half revenue totaled KRW 2,578B with operating profit of KRW 1,167B. Cumulative contract value reached USD 21.6B, reflecting sustained global demand for its integrated development and manufacturing services.

Performance was driven by favorable FX and full utilization of Plants 1–4 at Songdo's Bio Campus I. Despite batch disruptions from a May union strike, the company still posted a 44.4% operating margin. Plant 5's process performance qualification (PPQ) batches continue to ramp and are expected to lift H2 revenue. Samsung Biologics expects to reach the upper end of its 15–20% full-year revenue growth guidance.

Global expansion continues: following the March completion of the GSK Rockville acquisition — its first US manufacturing presence — the site is being integrated into the global network; a Netherlands sales office opens in Q3, completing coverage across the US (New Jersey), Japan (Tokyo) and Europe.

On innovation, the Life Science Fund — jointly created by Samsung Biologics, Samsung Bioepis and Samsung C&T — invested in Cartography Biosciences in May and committed an additional KRW 200B to create a third fund in June. The company is advancing proprietary platform technologies and expanding into ADC, peptides, AAV and other modalities. On ESG, it was included in the Dow Jones Best-in-Class Indices for the fifth consecutive year.